Thryv Therapeutics has presented new pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives acting as serum/glucocorticoid-regulated kinase 1 (SGK1) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders, Lafora disease and Parkinson's disease.